LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2005
Business Overview: A leading provider of clinical laboratory testing services, including routine, genomic, and esoteric testing. The company operates through a network of laboratories and joint ventures.

Key Financial Metrics

Note: Total Debt calculated as Zero coupon-subordinated notes ($536.3) + 5 1/2% senior notes ($353.3) + Long-term debt ($2.2) + Current portion of long-term debt ($0.1) + Capital lease obligations ($3.0).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6.2% ($46.6 million) driven by a 5.8% price increase and 0.4% volume growth. Volume growth was led by an 8.4% increase in genomic and esoteric testing, offset by a 1.2% decline in routine testing.
• Profitability: Net earnings rose 10.7% to $96.6 million. Operating margins improved slightly as Selling, General, and Administrative (SG&A) expenses decreased as a percentage of sales (21.0% vs. 21.6%) due to improved billing/collections and cost controls.
• Acquisitions: The company acquired US Pathology Labs ("US LABS") for approximately $155 million in cash in February 2005, contributing to increased goodwill ($90.4 million added) and amortization expenses.
• Liquidity: Cash and cash equivalents decreased significantly from $186.8 million to $71.7 million. This reduction was primarily due to $159.4 million used for business acquisitions and $112.0 million spent on stock repurchases.
• Debt Structure: The company entered a new $350 million senior credit facility in January 2005, replacing expiring facilities. No balances were outstanding on this facility as of March 31, 2005.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects total capital expenditures for 2005 to range between $110.0 million and $125.0 million, focused on customer retention, scientific differentiation, and IT connectivity.
• Future Acquisitions: On March 30, 2005, the company announced a definitive agreement to acquire Esoterix, Inc. for approximately $150 million in cash, expected to close in Q2 2005.
• Stock Repurchases: A new $250 million stock repurchase program was authorized on April 21, 2005, following the completion of $112.0 million in repurchases during Q1.
• Legal Contingencies:
  • Securities Litigation: Six consolidated shareholder class actions alleging securities fraud regarding 2002 disclosures remain pending. Management denies liability.
  • Patent Litigation: The company is appealing a $7.8 million judgment for patent infringement (paid) to the U.S. Supreme Court. The Solicitor General has been invited to weigh in on the validity of the patents.
  • Regulatory Risk: Ongoing exposure to federal and state regulations, including Medicare/Medicaid reimbursement policies and the False Claims Act (qui tam suits).
• Accounting Changes: The company is evaluating the impact of SFAS 123(R) regarding stock-based compensation, effective for periods beginning after June 15, 2005. Pro forma net income for Q1 2005 would have been $92.3 million under the new standard.

Investor Verification Checklist

• Acquisition Integration: Verify the financial impact and integration progress of the US Pathology Labs acquisition and the pending Esoterix, Inc. deal.
• Cash Position: Monitor the significant drawdown in cash reserves ($115 million decrease) and the company's ability to fund the Esoterix acquisition and ongoing operations without immediate debt issuance.
• Legal Outcomes: Track the status of the Supreme Court petition regarding the patent infringement case and the consolidated securities fraud litigation.
• Reimbursement Rates: Assess the impact of payer mix changes and potential regulatory shifts on the 5.8% price increase reported in the quarter.
• Stock-Based Compensation: Review the final impact of SFAS 123(R) adoption on future earnings per share when reported in Q4 2005.